Opinion|Videos|July 17, 2024
Use of Prophylactic Tocilizumab with Teclistamab: Takeaways from ASCO 2024
Author(s)Alfred L. Garfall, MD
Alfred L. Garfall, MD, discusses long-term follow-up data from the MajesTEC-1 study presented at ASCO 2024.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
1. Discuss the data presented at ASCO 2024 on long-term follow-up of patients receiving prophylactic tocilizumab for the reduction of cytokine release syndrome (CRS) in the phase 1/2 MajesTEC-1 study.
a. What is the background for using tocilizumab prior to administration of bispecific antibodies?
b. What methodology was used to study this cohort of patients?
c. What results were presented?
i. N=24
ii. Median follow-up: 8.1 months
iii. CRS occurred in 6 pts (25%; 2 grade 1, 4 grade 2, no grade ≥3)
iv. Reduced incidence of CRS with teclistamab vs overall MajesTEC-1 population
2. Please provide your key takeaways from this study. What are the implications of favorable safety results with the use of prophylactic tocilizumab?
3. In what patients are you currently using prophylactic tocilizumab? Who should be considered for it?
Advertisement
Related to this article
CDC data show cancer deaths declining as lung cancer treatment and detection advance, with new KRAS-targeted therapies showing early promise.
Nonadherence to semaglutide for obesity worsened once out-of-pocket costs passed roughly $75 per 30-day supply among commercially insured adults.
At a Stakeholder Interchange convened by The American Journal of Managed Care® in Houston, Texas, oncologists and pharmacists from academic and community practices debated how teclistamab- and talquetamab-based regimens stack up against CAR T-cell therapy in second-line multiple myeloma, and what it will take—staffing, caregiver support, hospital partnerships, and payer buy-in—to move step-up dosing out of the hospital and into the clinic.
All 50 states have applied for CMS's GENEROUS Model, a Medicaid drug pricing program expected to save $64.3 billion over the next decade.
HYPERION trial data shows a 76% reduction in clinical worsening events among adults recently diagnosed with PAH.
Diabetes care improves when support adapts to real-life changes, removing barriers and sustaining daily habits beyond reminders, education, and one-time interventions.
Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.
Global Burden of Disease data show prevalence fell nearly 30% from 1990 to 2021, yet the number of women affected grew 9.1%.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Imlunestrant Plus Abemaciclib for Breast Cancer
2
FDA Approves First Treatment for Sanfilippo Syndrome Type A
3
Higher CPAP Adherence Linked With Lower Mortality Risk in OSA
4
World Alzheimer Day: Young-Onset Alzheimer Disease Often Misdiagnosed
5